학술논문
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Kosiborod, Mikhail N ; Esterline, Russell; Furtado, Remo H M; Oscarsson, Jan; Gasparyan, Samvel B; Koch, Gary G; Martinez, Felipe; Mukhtar, Omar; Verma, Subodh; Chopra, Vijay; Buenconsejo, Joan; Langkilde, Anna Maria; Ambery, Philip; Tang, Fengming; Gosch, Kensey; Windsor, Sheryl L; Akin, Emily E; Soares, Ronaldo V P; Moia, Diogo D F; Aboudara, Matthew; Hoffmann Filho, Conrado Roberto; Feitosa, Audes D M; Fonseca, Alberto; Garla, Vishnu; Gordon, Robert A; Javaheri, Ali; Jaeger, Cristiano P; Leaes, Paulo E; Nassif, Michael; Pursley, Michael; Silveira, Fabio Serra; Barroso, Weimar Kunz Sebba; Lazcano Soto, José Roberto; Nigro Maia, Lilia; Berwanger, Otavio
Source
In The Lancet Diabetes & Endocrinology September 2021 9(9):586-594
Subject
Language
ISSN
2213-8587